XML 24 R11.htm IDEA: XBRL DOCUMENT
v3.25.3

Equity | 9 Months Ended
--- | ---
Sep. 30, 2025
Equity [Abstract] |
Equity | Equity Equity Distribution Agreements The Company has equity distribution agreements with three sales agents to sell up to $40,000,000 of its common stock from time-to-time in an at-the-market offering. During the three and nine months ended September 30, 2025 and 2024, the Company did not sell any shares. At September 30, 2025, the Company is authorized to sell an aggregate of $40,000,000 of shares pursuant to the equity distribution agreements. Common Stock Dividend Distribution The Company declared a quarterly cash distribution of $0.25 per share, payable on October 6, 2025, to stockholders of record on September 24, 2025. Share Repurchase Program Pursuant to the Company’s share repurchase program, as amended from time to time, the Company is authorized to repurchase shares of its common stock through open-market transactions, privately negotiated transactions, or otherwise. On March 11, 2025, the Board of Directors, replenished the value of the shares available to be purchased pursuant to this program to $10,000,000 of shares (a replenishment of $5,050,000 shares from the shares that were available to be repurchased prior to such increase) and extended the program through December 31, 2026. During the three months ended September 30, 2025, the Company did not repurchase any shares of common stock. During the nine months ended September 30, 2025, the Company repurchased 142,080 shares of common stock at an average price per share of $16.79 for an aggregate cost of $2,386,000. As of September 30, 2025, and October 31, 2025, up to $8,752,000 of shares were available to be repurchased under the program. Note 3 – Equity (continued) During the three months ended September 30, 2024, the Company repurchased 6,563 shares of common stock at an average price per share of $17.55 for an aggregate cost of $115,000. During the nine months ended September 30, 2024, the Company repurchased 183,243 shares of common stock at an average price per share of $18.08 for an aggregate cost of $3,312,000. Dividend Reinvestment Plan The Dividend Reinvestment Plan (the “DRP”), among other things, provides stockholders with the opportunity to reinvest all or a portion of their cash dividends paid on the Company’s common stock in additional shares of its common stock, at a discount, determined in the Company’s sole discretion, of up to 5% from the market price for the common stock (as such price is calculated pursuant to the DRP). The discount from the market price is currently 3%. During the three and nine months ended September 30, 2025, 53,787 and 150,416 shares were issued in lieu of cash dividends of $831,000 and $2,461,000, respectively. During the three and nine months ended September 30, 2024, 56,879 and 165,731 shares were issued in lieu of cash dividends of $951,000 and $2,829,000, respectively. Stock Based Compensation In June 2024, the Company's stockholders approved the 2024 Incentive Plan (the "2024 Plan"). This plan permits the Company to grant: (i) stock options, restricted stock, restricted stock units ("RSU's"), performance shares awards and any one or more of the foregoing, for up to a maximum of 1,000,000 shares; and (ii) cash settled dividend equivalent rights in tandem with the grant of restricted stock units and certain performance based awards. As of September 30, 2025, 449,226 shares are available for issuance pursuant to awards under the 2024 Plan. Awards to acquire 1,496,692 shares of common stock are outstanding under the 2024 Plan, the 2022 Incentive Plan (the "2022 Plan"), and the 2020 Amended and Restated Incentive Plan (the "2020 Plan"; and together with the 2022 Plan, the "Prior Plans"). No further awards may be granted pursuant to the Prior Plans. Restricted Stock Units As of September 30, 2025, an aggregate of 573,864 of unvested RSU's are outstanding pursuant to the 2024 Plan and the Prior Plans. Generally, the RSUs entitle the recipients, subject to continued service through the three-year vesting period to receive (i) the underlying shares if and to the extent certain performance and/or market conditions are satisfied at the vesting date, and (ii) an amount equal to the cash dividends that would have been paid during the three-year performance period with respect to the shares of common stock underlying the RSUs if, when, and to the extent, the related RSUs vest. The shares underlying the RSUs are not participating securities but are contingently issuable shares. For the three months ended September 30, 2025 and 2024, the Company recorded $166,000 and $303,000, respectively and for the nine months ended September 30, 2025 and 2024, the Company recorded $755,000 and $1,006,000 of compensation expense related to the amortization of unearned compensation with respect to the RSUs. At September 30, 2025 and December 31, 2024, $1,557,000 and $1,692,000 of compensation expense, respectively, has been deferred and will be charged to expense over the remaining vesting periods. The weighted average remaining vesting period of these restricted stock units is approximately 1.8 years. On July 11, 2025, the Company awarded an aggregate of approximately 195,413 shares subject to restricted stock units (“RSUs”), and related dividend equivalent rights. Generally, the awards vest in 2028 subject to satisfaction of, among other things, market and performance conditions. Restricted Stock In January 2025 and 2024, the Company granted 165,408 and 166,439 shares, pursuant to the 2024 Plan and 2022 Plan, respectively. As of September 30, 2025, an aggregate of 922,828 shares of unvested restricted stock are outstanding pursuant to the 2024 Plan and Prior Plans. The shares of restricted stock vest five years from the date of grant and under specified circumstances, including a change in control, may vest earlier. For financial statement purposes, the restricted stock is not included in the outstanding shares shown on the consolidated balance sheets until they vest, but is included in the earnings per share computation. For the three months ended September 30, 2025 and 2024, the Company recorded $1,078,000 and $886,000, respectively and for the nine months ended September 30, 2025 and 2024, the Company recorded $2,766,000 and $2,615,000, of compensation expense related to the amortization of unearned compensation with respect to the restricted stock awards. At September 30, 2025 and December 31, 2024, $6,577,000 and $6,660,000, respectively has been deferred as unearned compensation and will be charged to expense over the remaining vesting periods of these restricted stock awards. The weighted average remaining vesting period of these restricted stock awards is 2.1 years. Note 3 – Equity (continued) Per Share Data Basic earnings per share is determined by dividing net income applicable to common stockholders for the applicable period by the weighted average number of shares of common stock outstanding during such period. Net income is also allocated to the unvested restricted stock outstanding during each period, as the restricted stock is entitled to receive dividends and is therefore considered a participating security. The RSUs are excluded from the basic earnings per share calculation as they are not participating securities. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into shares of common stock or resulted in the issuance of shares of common stock that share in the earnings of the Company. Diluted earnings per share is determined by dividing net income applicable to common stockholders for the applicable period by the weighted average number of shares of common stock deemed to be outstanding during such period. In calculating diluted earnings per share, the Company includes only those shares underlying the RSUs that it anticipates will vest based on management's estimates as of the end of the most recent quarter. The Company excludes any shares underlying the RSUs from such calculation if their effect would have been anti-dilutive. The following table provides a reconciliation of the numerator and denominator of earnings per share calculations (amounts in thousands, except per share amounts:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Numerator for basic and diluted earnings per share: |  |  |  |  |  |  |
Net loss | $ | (2,668) |  |  | $ | (2,167) |  |  | $ | (7,499) |  |  | $ | (7,612) |
Deduct net income attributable to non-controlling interests | (39) |  |  | (38) |  |  | (126) |  |  | (109) |
Deduct loss allocated to unvested restricted stock | 132 |  |  | 113 |  |  | 373 |  |  | 398 |
Net loss available for common stockholders: basic and diluted | $ | (2,575) |  |  | $ | (2,092) |  |  | $ | (7,252) |  |  | $ | (7,323) |
Denominator for basic earnings per share: |  |  |  |  |  |  |
Weighted average number of common shares outstanding | 18,028,496 |  |  | 17,796,206 |  |  | 18,000,615 |  |  | 17,720,024 |
Effect of dilutive securities: |  |  |  |  |  |  |
RSUs | — |  |  | — |  |  | — |  |  | — |
Denominator for diluted earnings per share: |  |  |  |  |  |  |
Weighted average number of shares | 18,028,496 |  |  | 17,796,206 |  |  | 18,000,615 |  |  | 17,720,024 |
Loss per common share, basic and diluted | $ | (0.14) |  |  | $ | (0.12) |  |  | $ | (0.40) |  |  | $ | (0.41) |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration